Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Navidea Biopharma (NAVB) Reports Q2 Loss of $0.24
August 8, 2019 5:35 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.24), versus ($0.29) reported last year. Revenue for the quarter came in at $260.09 million, versus $542.13 million reported last year.
Second Quarter 2019 Highlights and Subsequent Events
Effected a one-for-twenty reverse stock split and received notification of stock price compliance from the NYSE AmericanAnnounced that results of the Companys NAV3-21 clinical study for diagnosis of rheumatoid arthritis were presented at the... More